139th Day Of Lockdown

Maharashtra51533235171017757 Tamil Nadu2969012386384927 Andhra Pradesh2278601387122036 Karnataka178087939083198 Delhi1454271305874111 Uttar Pradesh122609726502069 West Bengal95554671202059 Bihar7972051315429 Telangana7949555999627 Gujarat71064542382652 Assam5883842326145 Rajasthan5249738235789 Odisha4592731785321 Haryana4163534781483 Madhya Pradesh3902529020996 Kerala3433121832109 Jammu and Kashmir2489717003472 Punjab2390315319586 Jharkhand185168998177 Chhatisgarh12148880996 Uttarakhand96326134125 Goa871259575 Tripura6161417641 Puducherry5382320187 Manipur3752204411 Himachal Pradesh3371218114 Nagaland27819048 Arunachal Pradesh215514823 Chandigarh151590425 Meghalaya10624906 Sikkim8664971 Mizoram6082980
Science 03 Jul 2020 Zydus Cadila's ...

Zydus Cadila's potential COVID drug may begin human clinical trials

PTI
Published Jul 3, 2020, 10:55 am IST
Updated Jul 3, 2020, 10:55 am IST
India’s 'first' indigenous COVID-19 vaccine candidate Covaxin had also got the nod for human clinical trials recently
Representational Image. (AP)
 Representational Image. (AP)

New Delhi: A potential COVID-19 vaccine indigenously developed by the Ahmedabad-based Zydus Cadila Healthcare Ltd has got the nod from the Drugs Controller General of India (DCGI) for human clinical trials, according to a government source.

The approval process was fast-tracked following a recommendation by the subject expert committee on COVID-19, considering the emergency and unmet medical need during the pandemic.

 

"DCGI Dr V G Somani has given approval for the phase I and II clinical trials (on humans) of the potential novel coronavirus vaccine developed by Zydus Cadila Healthcare Ltd on Thursday after its animal studies were found to be successful," an official source in the know of the developments told PTI.

The assent for human trials was given after the company submitted data of clinical trial on animals to the DCGI, in which the vaccine candidate was found to be successful with respect to safety and immunogenicity, the source said.

The company is likely to start enrolment of subjects soon.

 

"The phase I and II trials will take around three months to be completed," the source said.

The country's 'first' indigenous COVID-19 vaccine candidate Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research and National Institute of Virology (NIV), had recently got the nod for human clinical trials from the DCGI.

India's COVID-19 tally rose to 6,04,641 on Thursday with a single-day increase of 19,148 cases, just five days after it crossed the five-lakh mark, while the death toll rose to 17,834 with 434 new fatalities, according to the Union Health Ministry.

 

Click on Deccan Chronicle Technology and Science for the latest news and reviews. Follow us on Facebook, Twitter

...
Location: India, Delhi, New Delhi




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT